The estimated Net Worth of Michael V. Williamson is at least $10.9 Milión dollars as of 1 July 2019. Mr Williamson owns over 5,000 units of Axonics Inc stock worth over $10,468,816 and over the last 6 years he sold AXNX stock worth over $394,050.
Mr has made over 2 trades of the Axonics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he sold 5,000 units of AXNX stock worth $214,000 on 1 July 2019.
The largest trade he's ever made was selling 5,000 units of Axonics Inc stock on 1 July 2019 worth over $214,000. On average, Mr trades about 3,333 units every 5 days since 2019. As of 1 July 2019 he still owns at least 152,318 units of Axonics Inc stock.
You can see the complete history of Mr Williamson stock trades at the bottom of the page.
Michael V. Williamson is the Sr. VP, Gen. & IP Counsel at Axonics Inc.
Mr Williamson is 50, he's been the Sr. VP a Gen. & IP Counsel of Axonics Inc since . There are 13 older and 8 younger executives at Axonics Inc. The oldest executive at Axonics Inc is Nancy Snyderman, 68, who is the Independent Director.
Michael's mailing address filed with the SEC is 26, Technology Drive, Irvine Spectrum, Irvine, Orange County, California, 92618, United States.
Over the last 6 years, insiders at Axonics Inc have traded over $108,010,643 worth of Axonics Inc stock and bought 4,672,163 units worth $70,180,620 . The most active insiders traders include Asset Management, Lp Chen B..., Shahzad Malik a Geoff Pardo. On average, Axonics Inc executives and independent directors trade stock every 15 days with the average trade being worth of $4,280,711. The most recent stock trade was executed by Raymond W Cohen on 24 July 2024, trading 103,896 units of AXNX stock currently worth $2,383,374.
axonics modulation technologies, inc is a privately-held medical device company developing an innovative neuromodulation platform based on a miniaturized rechargeable fully-implantable ipg licensed from the alfred mann foundation. the axonics sacral neuromodulation system is designed to improve the experience of both clinicians and patients suffering from urinary and fecal dysfunction.
Axonics Inc executives and other stock owners filed with the SEC include: